A groundbreaking telehealth trial offers remote access to innovative pancreatic cancer treatment, enhancing patient ...

BACKGROUND: Recent studies have highlighted the deleterious role of high phosphate intake in hypertension by means of ...

A trial of Incyte's Pemazyre in patients with FGFR-altered brain cancer did not meet its primary endpoint but had encouraging secondary outcomes.

Co-lead author of the study, Dr. Volker Hovestadt, explained, "We discovered that FGFR and NOTCH receptors are expressed by proliferative NSC-like cells, while more differentiated malignant cells ...

Gain-of-function mutations in fibroblast growth factor receptor (FGFR) genes are known to cause a range of skeletal disorders, such as craniosynostosis and chondrodysplasia, which severely affect ...

A new study explores the potential of fibroblast growth factor receptor (FGFR) antagonists in restoring defective mandibular bone repair in mouse models of osteochondrodysplasia, a group of ...

Despite an outcome that TD Cowen analyst Tyler Van Buren called ”fantastic,” shares of Tyra Biosciences Inc. (NASDAQ:TYRA) closed Oct. 25 at $21.93, down $6.68, or 23%, as Wall Street digested new ...

Infigratinib, a fibroblast growth factor receptor (FGFR) inhibitor, had received accelerated approval in 2021 for previously treated, unresectable locally advanced or metastatic cholangiocarcinoma ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window CHICAGO -- Patients with FGFR-mutated advanced urothelial cancer that progressed after anti-PD-1/L1 therapy lived ...

Erdafitinib is an oral medication that blocks the activity of FGFR signaling proteins, which are important for a variety of normal cellular processes. However, FGFR genetic alterations can drive ...